Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Emmaus Life Sciences Inc
EMMAEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers. The company was founded in 2000 and is headquartered in Torrance, California. Address: 21250 Hawthorne Boulevard, Torrance, CA, United States, 90503
Analytics
Precio Objetivo de WallStreet
4 USDRelación P/E
–Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave EMMA
Análisis de dividendos EMMA
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout EMMA
Valoración de la acción EMMA
Finanzas EMMA
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |